

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

GRUENBERG, MICHEAL L.

Serial No.:

08/700,565

Filed:

July 25, 1996

For:

AUTOLOGOUS IMMUNE CELL

THERAPY: CELL

COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN

DISEASE

Art Unit:

\_1815 / 644

Examiner:

Schwadron, R.

27

TECH CENTER 1800/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE WITH 37 C.F.R. § 1.97(b) and 1.98

Assistant Commissioner for Patents Washington, D.C. 20231

## Dear Sir:

Because this Supplemental Information Disclosure Statement is filed after receipt of a First Office Action on the merits for the above-captioned application, the filing fee of \$240/- is enclosed. If no proper payment is enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 08-1641.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §1.97-1.98. Forms PTO-1449 (2 pages) and copies of the cited references are

## U.S.S.N. 08/700,565 GRUENBERG SUPPLEMENTAL IDS

٥

provided herewith, by hand delivery, in connection with the above-captioned application.

In furtherance to Information Disclosure Statement mailed November 21, 1996, listing co-pending application U.S.S.N. 08/506,173, enclosed is U.S. Patent No. 5,627,070, which has issued since the above co-pending application was listed, and U.S. Patent No. 5,763,261, which is a continuation of U.S. Patent No. 5,627,070. Both patents have the same inventor (Gruenberg, Micheal) and owner (CellTherapy) as the above-referenced application.

All documents listed on the Form PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant also makes known to the Examiner the following related, copending applications, which are divisional applications of the above-referenced application:

<u>U.S.S.N.</u>	<u>Inventor</u>	Filing Date
09/127,411	Gruenberg	07/31/98
09/127,142	Gruenberg	07/31/98
09/127,138	Gruenberg	07/31/98
09/127,141	Gruenberg	07/31/98

Applicant respectfully requests that the Examiner review the foregoing

U.S.S.N. 08/700,565 GRUENBERG SUPPLEMENTAL IDS

references and make it of record in the file history of the above-caption d application.

Respectfully submitted, HELLER, EHRMAN, WHITE & McAULIFFE

By: Stephanie Seidman

Registration No. 33,779

Attorney Docket No. 24731-500B

Address all correspondence to:
HELLER, EHRMAN, WHITE & McAULIFFE
4250 Executive Square,
La Jolla, California 92037
Telephone: (619) 450-8400

E-Mail: sseidman@hewm.com